Skip to main content
Premium Trial:

Request an Annual Quote

DeCode Posts Q1 Revenue Increase, Narrowed Losses

NEW YORK, May 14 - DeCode Genetics reported an increase of first-quarter revenues today, amid narrowed net losses.

 

The Reykjavik, Icelandpopulation genomics company had revenues of $11.8 million for the first quarter, compared to $5.3 million for the same period last year.

 

The company's R&D expenses increased slightly to $19.8 million, compared to $18.8 million for the year-ago period. DeCode said this increase partly reflected the acquisition of its pharmaceuticals and biostructures groups.

 

In total, the company's net losses came to $13.0 million, compared to $15.9 million for the first quarter of 2002.

 

As of March 31, DeCode had $79.2 million in cash and cash equivalents.

 

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.